Abstract:315 Background: Invasive procedures including biopsies in freshly irradiated tissue is a known risk factor for high-grade toxicity. Screening colonoscopies (CS) are often performed before radiotherapy given the need to rule out comorbid gastrointestinal conditions and avoid untoward post radiotherapy instrumentation of the pelvis. We investigate the association of pre-treatment CS and the colonic finding therein with subsequent GI toxicity following SBRT for prostate cancer. Methods: An institutional registry of patients undergoing five-fraction prostate SBRT was interrogated to identify those who underwent screening CS prior to radiotherapy from Feb. 2021 – May 2023. Patients were categorized into those who did and did not undergo CS within 6 months of SBRT. A detailed analysis of CS findings including polyp resection as well as presence of diverticulosis and hemorrhoids was performed. Post-SBRT toxicity was evaluated using CTCAE v 5.0. Groups were compared using the chi-square or Fisher’s exact test for categorical variables. The Mann-Whitney test was used to compare groups for time from CS to SBRT and presented as median (25 th , 75 th percentiles). A result was considered significant at p < 0.05. Results: In this cohort, a total of 156 patients underwent prostate SBRT with the distribution of risk grouping was as follows: low 9% (n = 14), intermediate 67% (n = 104), and high 24% (n = 38). Of the entire group, a total of 138 patients underwent pre-treatment CS with a median time from CS to SBRT of 4 months. There was no difference in grade 1+ GI toxicity (67% vs. 61%, p = 0.60) in patients who did and did not undergo pretreatment CS. However, there was a significantly higher grade 2+ GI toxicity in patients who did not undergo pretreatment CS (45% vs. 15%, p = 0.03). Of the 138 subjects who underwent CS, time from CS to SBRT was not different between those who did and did not have any GI toxicity (4.6 months versus 3.3 months, p = 0.08) or between those who had grade 1 vs. grade 2+ toxicity (4.6 versus 4.7 months, p = 0.65). Notably, there was not an increased rate of GI toxicity in patients found to have diverticulosis (61.1% vs. 74.2%, p = 0.11), hemorrhoids (62.3% vs. 70.6%, p = 0.31), or resected polyps (70% vs. 64.7%, p = 0.51) on pre-SBRT CS. Finally, patients who had polyps resected in the rectosigmoid did not have a higher rate of GI toxicity versus those who under polyp resection elsewhere in the colon (57.6% vs. 71.4% respectively, p = 0.23). Conclusions: Pretreatment CS was not associated with an increased risk of GI toxicity following prostate SBRT, and in fact was associated with a lower rate of grade 2+ GI toxicity. Moreover, identification of polyps requiring resection (in the rectosigmoid or elsewhere), diverticulosis, and hemorrhoids on pretreatment CS did not result in excess GI toxicity following SBRT.

High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy

High-risk prostate cancer treated with a stereotactic body radiation therapy boost following pelvic nodal irradiation

Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy

Stereotactic Body Radiation Therapy for the Curative Treatment of Prostate Cancer in Ultralarge (≥100 cc) Glands

Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective Trials

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients

Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies

Dose-Intensified Stereotactic Ablative Radiation for Localized Prostate Cancer

Long-term treatment outcomes from the International Multi-Institutional Stereotactic Body Radiation Therapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium.

Dose–response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control

Salvage Stereotactic Radiotherapy for Nodal Oligo-recurrent Prostate Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched Analysis

Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial

Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy—implications on clinically-significant prostate cancer detection and relevance to focal therapy planning

Evaluation of the safety and efficacy of high-dose rate brachytherapy for radiorecurrent prostate cancer: a systematic review and meta-analysis

Salvage re-irradiation using stereotactic body radiation therapy for locally recurrent prostate cancer: the impact of castration sensitivity on treatment outcomes

Pretreatment colonoscopy impact on acute gastrointestinal (GI) toxicity following curative stereotactic body radiation therapy (SBRT) for localized prostate cancer.

A Phase II Trial of Stereotactic Ablative Body Radiotherapy for Low-Risk Prostate Cancer Using a Non-Robotic Linear Accelerator and Real-Time Target Tracking: Report of Toxicity, Quality of Life, and Disease Control Outcomes with 5-Year Minimum Follow-Up

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost